Jeannette Potts Sells 5,237 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 5,237 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the sale, the insider directly owned 133,246 shares of the company’s stock, valued at approximately $3,686,916.82. This represents a 3.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Stock Down 3.9%

NASDAQ:QURE opened at $46.29 on Friday. The stock’s fifty day moving average price is $24.13 and its two-hundred day moving average price is $22.03. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, analysts anticipate that uniQure N.V. will post -3.64 EPS for the current year.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of research reports. HC Wainwright restated a “buy” rating on shares of uniQure in a research report on Thursday. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research report on Wednesday. Wolfe Research began coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Finally, Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Twelve equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $58.92.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Jones Financial Companies Lllp increased its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 533 shares during the period. Arizona State Retirement System increased its stake in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares during the period. Finally, FNY Investment Advisers LLC boosted its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now suggests uniQure can move ahead with a BLA submission for AMT-130 using existing mid-stage data, significantly improving the regulatory timeline. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight and raised its price target, reflecting improved confidence in the company’s Huntington’s program. Seeking Alpha
• Positive Sentiment: Barclays also upgraded the stock and lifted its target, adding to the wave of bullish analyst sentiment after the FDA development. Benzinga
• Neutral Sentiment: There were insider sales disclosed this week, including transactions by directors and executives, but these appear to be routine filings and are being overshadowed by the FDA-driven rally.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.